Track the Ocata Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 11 February 2016 (U). Among the most active insiders: SHAPIRO ALAN C. All data is accessible without an account.
21
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ocata Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 26,657 of 28,901 companies
19.3
score / 100
Value
23
Quality
16
FCF yld-4.0%
Earn yld-5.1%
EV/EBITDA·
ROE-40%
Gross mgn19%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Ocata Therapeutics, Inc. is a biotechnology company focused on developing stem cell-based therapies for treating eye diseases. It is listed on NASDAQ under the ticker OCAT.